| Gene |
[CLRN1](/genes/clrn1) |
| UniProt |
Q9NYQ5 |
| PDB |
6UUS |
| Mol. Weight |
~24 kDa |
| Localization |
Plasma membrane, synaptic vesicles |
| Family |
Clarin family, tetraspanin-like proteins |
| Diseases |
[Usher Syndrome](/diseases/usher-syndrome), [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa) |
Clarin 1 is a protein encoded by the CLRN1 gene. It belongs to the clarin family of tetraspanin-like proteins and has a molecular weight of approximately 24 kDa. This protein is localized to the plasma membrane and synaptic vesicles, playing essential roles in sensory system function.
Clarin 1 is a small membrane protein with four transmembrane domains, similar to the tetraspanin superfamily. The protein contains:
- Four transmembrane helices
- N-terminal extracellular domain
- C-terminal cytoplasmic tail
- Conserved cysteine residues in the extracellular loops
The N48K mutation (asparagine to lysine at position 48) is the most common pathogenic variant causing Usher syndrome type 3A (USH3A) 1.
In the normal nervous system, clarin 1 is expressed primarily in:
- Retina: Photoreceptor cells (rods and cones)
- Cochlea: Hair cells of the inner ear
The protein plays critical roles in:
- Synaptic vesicle organization and function
- Hair cell stereocilia maintenance
- Photoreceptor synaptic ribbon function
- Calcium homeostasis in sensory cells
Clarin 1 interacts with other Usher syndrome proteins including USH2A (usherin) and VLGR1 (very large G-protein coupled receptor 1) to form a protein complex essential for sensory cell function 2.
Clarin 1 mutations cause Usher syndrome type 3A (USH3A), characterized by:
- Progressive hearing loss: Sensorineural hearing loss beginning in childhood
- Retinitis pigmentosa: Progressive vision loss due to photoreceptor degeneration
- Variable vestibular dysfunction: Balance problems in some patients
While not a classical neurodegenerative disease, clarin 1 deficiency leads to:
- Synaptic dysfunction: Impaired neurotransmitter release from photoreceptor and hair cell synapses
- Stereocilia degeneration: Loss of the organized hair bundle structure essential for mechanotransduction
- Photoreceptor cell death: Progressive degeneration of rod and cone cells
- Calcium dysregulation: Altered calcium signaling in sensory cells
The N48K mutation leads to protein misfolding, retention in the endoplasmic reticulum, and degradation via the ER-associated degradation (ERAD) pathway 3.
- AAV-mediated gene delivery: Clinical trials are underway using adeno-associated viruses to deliver functional CLRN1 copies to the retina and inner ear 4
- CRISPR/Cas9 approaches: Gene editing strategies to correct specific mutations are in development
- Protein folding correctors: Small molecules being investigated to rescue mutant protein trafficking
- Antioxidants: To address potential oxidative stress in sensory cells
- Neuroprotective agents: To slow photoreceptor degeneration
Several clinical trials are investigating gene therapy for USH3A:
- CLRN1-101 (ClinicalTrials.gov NCT02828042): Phase I/II gene therapy trial
- AAV2/5-MTVP-USH3A: Intravitreal gene delivery
- Joensuu et al., Mutations in a novel gene, clarin-1, cause Usher syndrome type 3A (2009)
- Zallocchi et al., Role of clarin-1 in USH3A pathogenesis (2010)
- Geleoc & El-Amraoui, Mechanisms of USH3A pathogenesis (2014)
- Gene therapy for Usher syndrome type 3A (2020)